-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Zhe Wang, MD, PhD1*, Anna Skwarska, PhD2, Gowri Poigailwar2*, Sovira Chaudhry, MSc2*, Alba Rodriguez-Meira, PhD3,4*, Pinpin Sui, PhD5*, Emmanuel Olivier, PhD6,7*, Yannan Jia1,8*, Cassandra L. Ramage1*, Guangrong Zheng, PhD9*, Alexandra Schurer, MS2, Kira Gritsman, MD, PhD10, Eirini Papapetrou, MD, PhD6,7, Kapil N. Bhalla, MD1, Daohong Zhou, MD11*, Adam J Mead, PhD, MRCP, FRCPath12, Raajit Rampal, MD, PhD13, Jeffrey W Tyner, PhD14*, Hussein A. Abbas, MD, PhD1, Naveen Pemmaraju, MD15, Qi Zhang Tatarata, MD, PhD1,16* and Marina Konopleva1,2

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
3Broad Institute of MIT and Harvard, Cambridge, MA
4Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA
5Department of Cell Systems & Anatomy, The University of Texas Health Science Center at San Antonio, San Antonio, TX
6Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
7Center for the Advancement of Blood Cancer Therapies, Institute for Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
8Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL
10Albert Einstein College of Medicine, Bronx, NY
11Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX
12Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
13Memorial Sloan Kettering Cancer Center, New York, NY
14Knight Cancer Institute, Oregon Health & Science University, Portland, OR
15Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
16NYC Health + Hospital/ Kings County Hospital, SUNY Downstate Health Sciences University, Brooklyn, NY

Frances M. Cole1*, George S. Laszlo, PhD2*, Margaret C. Lunn-Halbert1*, Allie R. Kehret1*, Patrick A. Zweidler-McKay, MD, PhD3, Eduardo Rodríguez-Arbolí, MD, MPhil1,4*, David Wu, MD, PhD5*, Kyle E. Nyberg1*, Junyang Li1*, Sheryl Y. T. Lim, DPhil1*, Sribalaji Lakshmikanthan, PhD3* and Roland B. Walter, MD, PhD, MS6,7,8

1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
21100 Fairview Avenue North, Fred Hutchinson Cancer Center, Seattle, WA
3ImmunoGen, Inc., Waltham, MA
4Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, University of Seville, Seville, Spain
5Hematopathology, University of Washington, Seattle, WA
6Fred Hutchinson Cancer Center, Seattle, WA
7Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA
8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA

Manuela Albuquerque De Melo, MSc1*, Diego A. Pereira-Martins, Ph.D.2*, Brunno Gilberto Santos Macedo, MSc1*, Livia Bassani Lins de Miranda, Bsc3*, Priscila Santos Scheucher, PhD1*, Isabel Weinhäuser, PhD4*, Gerwin Huls2, Jan Jacob Schuringa, Prof. Dr.2, João Agostinho Machado-Neto, PhD3* and Fabiola Traina, MD, PhD1

1Department of Medical Images, Hematology, and Oncology, University of São Paulo at Ribeirão Peto Medical School, Ribeirão Preto, Brazil
2Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, Groningen, Netherlands
3Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
4Department of Experimental Hematology, University Medical Center Groningen, Groningen, Netherlands

Vakul Mohanty, PhD1*, Natalia Baran, MD, PhD2,3, Yuefan Huang4*, Cassandra L. Ramage2*, Laurie Cooper5*, Sarah Gwen Pelletier, BS2*, Shan He4*, Ramiz Iqbal4*, May Daher, MD, MD6, Jeffrey W. Tyner, PhD7, Gordon B Mills8*, Marina Konopleva9 and Ken Chen, PhD1*

1Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Section of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
4Department of Bioinformatics and Computational biology, The University of Texas MD Anderson Cancer Center, Houston, TX
5The University of Texas MD Anderson Cancer Center, Houston
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Knight Cancer Institute, Oregon Health & Science University, Portland, OR
8Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
9Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY

Xiyang Ren1*, Haotian Yan1*, Mei Zhou1*, Fan Wu2*, Qing Zhang1*, Yangyang Ding, MD3*, Qian Li, MD4*, Huiping Wang5*, Caixian Xu5*, Jiyu Wang6*, Cong Li2*, Wanqiu Zhang2*, Linlin Liu1*, Ruotong Chen5*, Yi Dong1*, Wenjie Dai5*, Zhimin Zhai, MD7 and Qianshan Tao, MD8*

1The Second Affiliated Hospital of Anhui Medical University, Hefei, China
2Hematologic Department/Hematologic Diseases Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
3Hematologic Department/Hematologic Diseases Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
4Center of Hematology Research, Anhui Medical University, Hefei, China
5Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
6Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, AL, China
7The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
8Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Yuki Nishida, MD, PhD1, Hideaki Mizuno, MD, PhD1*, Edward Ayoub, PhD1*, Eiji Sugihara, PhD2*, Lauren B. Ostermann, BSc1*, Shayaun Khazaei, BS1*, Darah Scruggs, MS1*, Po Yee Mak1*, Baozhen Ke, BS1*, Bing Z. Carter, PhD1, Abhishek Maiti, MBBS3, Liandong Ma, PhD4* and Michael Andreeff, MD, PhD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Fujita Health University, Division of Gene Regulation, Cancer Center and Open Facility Center, Research Promotion Headquarters, Toyoake, JPN
3Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
4Oncobiotherapeutics, Radnor, PA

Daniel J Vail1*, Jill Durkin2*, Dongxu Jiang, PhD1, Thomas Laframboise, PhD3* and Babal K. Jha, PhD1,4

1Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
2Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Bay Village, OH
3Case Western Reserve University, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Ida Vänttinen1,2*, Joseph Saad, MSc1,2*, Tanja Ruokoranta, MSc2*, Sari Kytölä, MD3*, Pia-Sofia Ettala, MD4*, Marja Pyörälä, MD, PhD5*, Johanna Rimpiläinen, MD6*, Timo Siitonen, MD, PhD7*, Caroline A. Heckman, PhD1,2, Heikki Kuusanmäki, PhD1,2,8* and Mika Kontro, MD, PhD1,2,3,8

1iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
2Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
3Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
4Department of Clinical Hematology, Turku University Hospital, Turku, Finland
5Department of Medicine, Kuopio University Hospital, Kuopio, Finland
6Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
7Department of Hematology, Oulu University Hospital, Oulu, Finland
8Foundation for the Finnish Cancer Institute, Helsinki, Finland

Yueming Tang, MD, PhD1*, Adam Braun, MD2*, Zachary von Behren3*, Jieya Wu, MD4*, Caitlyn Haley3*, Chunxiao Zhang, PhD5*, Brenda Loera5*, Pina M. Cardarelli, Ph.D.6, Nina Caculitan, PhD6*, Sylvia Chien7*, Jin Dai, PhD7*, Vivian G. Oehler, MD8*, Jianying Zhang, PhD9*, Guido Marcucci10 and Pamela S. Becker, MD, PhD11,12

1Department of Hematologic Malignancies Translational Science, City of Hope, Monrovia, CA
2City of Hope, Duarte, CA
3City of Hope, Monrovia, CA
4Department of Hematologic Malignancies Translational Science, City of Hope National Medical Center, Monrovia, CA
5Amgen, Thousand Oaks, CA
6GPCR Therapeutics, Redwood City, CA
7University of Washington, Seattle, WA
8Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
9Department of Computational and Quantitative Medicine, Duarte, CA
10Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA
11Department of Hematologic Malignancies Translational Science, City of Hope Beckman Research Institute, Duarte, CA
12Hematology/HCT, City of Hope, Duarte, CA

Priyanka Sharma, PhD1, Natalia Baran, MD, PhD2, Qi Zhang, PhD2*, M. Anna Zal, M.Sc.3*, Joanne Munck, PhD4*, Martin Sims, PhD4*, Bing Z. Carter, PhD1, Michael Andreeff, MD, PhD1 and Gautam Borthakur, MD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX
4Astex Pharmaceuticals, Cambridge, United Kingdom

Zhe Wang, MD, PhD1*, Cassandra L. Ramage1*, Helen Ma1*, Haichao Zhang2*, Andrew Souers, PhD3, Darren C Phillips, PhD, BSc2*, Marina Konopleva4 and Qi Zhang Tatarata, MD, PhD1,5*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Abbvie, North Chicago, IL
3AbbVie Inc., North Chicago, IL
4Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
5NYC Health + Hospital/ Kings County Hospital, SUNY Downstate Health Sciences University, Brooklyn, NY

Ebubechukwu Osinachi Nwarunma, MSc, BSc1*, Katerina Miari, PhD2*, Athanasia Papadopoulou, MSc3*, Leandro Martinez, PhD4*, Victoria Campbell, MD, PhD5*, Samantha Hurwitz, PhD6, Tatiana Fourfouris, MSc6, Ki Jun Lee, MSc6, Carl Goodyear, PhD7*, Theodoros Simakou, PhD7*, Marcus Doohan, BSc7*, Lucy MacDonald, PhD7*, Timothy Humpton, PhD3,8*, Lesley Forrester, PhD9*, Mariola Kurowska-Stolarska, PhD7*, Ken I Mills, PhD, FRCPath10, Yong-Mi Kim, MD, PhD, MPH6, Helen Wheadon, PhD2*, Monica L Guzman, PhD11 and Mark T Williams, PhD3,12*

1Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, SCO, United Kingdom
2Paul O’Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
3Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, United Kingdom
4Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
5Department of Haematology, Western General Hospital, Edinburgh, United Kingdom
6Children's Hospital of Los Angeles, University of Southern California, Los Angeles, CA
7School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom
8Cancer Research UK Scotland Institute, Glasgow, United Kingdom
9Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom
10Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, NI, United Kingdom
11Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
12School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

Yingying Yang, MSc1*, Ekaterina Parfenova2, Nikolina Vrdoljak, BSc3*, Mark D. Minden, MD, PhD4,5,6,7,8*, Jessica Luc9*, Andrew Doxey, Ph.D.9* and Paul A. Spagnuolo, PhD10*

1Food Science, University of Guelph, Guelph, ON, Canada
2Department of Food Science, University of Guelph, Guelph, ON, CAN
3Department of Food Science, University of Guelph, Georgetown, ON, Canada
4Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
6Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
7Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
8Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
9Department of Biology, University of Waterloo, Waterloo, ON, Canada
10Department of Food Science, University of Guelph, Guelph, ON, Canada

Xiaoyuan Zeng1,2*, Kwui-Wa Tong1,2*, Koon Chuen Chan1,2*, Li-Chuan Zheng1,2*, Stephen Lam, PhD, MBBS,1*, Mark Robert Bray, PhD3*, Tak-Wah Mak, PhD2,3,4*, Cheuk-Him Man, PhD1* and Anskar Y. H. Leung, MD, PhD1,2

1Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
2Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China
3Princess Margaret Cancer Centre, The Campbell Family Institute for Breast Cancer Research, Toronto, Canada
4Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Emily E Hartung1,2*, Kanwaldeep Singh, PhD1,3*, Sarah Coopersmith, BSc1,2*, Jamie Avrumutsoae1,2*, Siddaarth Varatharajan1,2*, Sara Pishyar, MSc1,2*, Pradhariny Prabagaran, MSc1,2*, Dina Khalaf, MSc, MBBS3, Alejandro Garcia-Horton, MD3, Ronan Foley, MD, FRCPC3*, Brian Leber, MD4, Irwin Walker, MBBS4, Kylie L. Lepic, MD3*, Maria Kleppe, PhD, RPh5*, Hugh Young Rienhoff Jr., MD5 and Tobias Berg, MD1,3,6

1Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
2Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
3Department of Oncology, McMaster University, Hamilton, ON, Canada
4Department of Medicine, McMaster University, Hamilton, ON, Canada
5Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ
6Escarpment Cancer Research Institute, Hamilton Health Sciences / McMaster University, Hamilton, ON, Canada

Kazuharu Kamachi, MD, PhD1*, Hiroki Akiyama, MD, PhD1,2, Ran Zhao, MSc1*, Liang Zhang, PhD1*, Saurabh Kumar Gupta, PhD1*, Lauren B. Ostermann, BSc1*, Yuji Otsuki, MD, PhD3*, Osamu Nagano, DDS, PhD3*, Hideyuki Saya, MD, PhD3*, Ayumu Taguchi, MD, PhD4*, Michael Andreeff, MD, PhD1 and Jo Ishizawa, MD, PhD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan
3FerroptoCure, Tokyo, Japan
4Division of Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan

Abdullah Khasawneh1*, Faith Jessica Paran, PhD2*, Abhishek Maiti, MBBS3, Bofei Wang, PhD4, Kala Hayes, PhD5*, Courtney D. DiNardo, MD, MSc6, Michael Andreeff, MD, PhD7, Hussein A. Abbas, MD, PhD5, Marina Konopleva5,8 and Yoko Tabe, MD, PhD9,10*

1Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo, Japan
2Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
3Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
4Department of Leukemia, Division of Cancer Medicine, The University of Texas At MD Anderson Cancer Cent, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
9Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Tokyo, Japan

Kentson Lam, MD, PhD1, Yoon Joon Kim2*, Carlo M. Ong2*, Andrea Z. Liu2*, Fanny Jiahua Jiahua Zhou, BS, MS3, Bernadette A. Chua, PhD2*, Silvia Vicenzi, PhD4, Pierce W. Ford5*, Jie-Hua Zhou6*, Eric Bennett5*, Leslie A Crews, PhD7, Edward D. Ball, MD6 and Robert Signer, PhD8

1Division of Regenerative Medicine, Department of Medicine, Sanford Stem Cell Institute, Moores Cancer Center, University of California, San Diego, San Diego, CA
2Division of Regenerative Medicine, Department of Medicine, Sanford Stem Cell Institute, Moores Cancer Center, University of California, San Diego, La Jolla, CA
3Division of Regenerative Medicine, Department of Medicine, Stem Cell Discovery Center, Sanford Stem Cell Institute, Moores Cancer Center, University of California San Diego, San Diego, CA
4Moores Cancer Center, UNIVERSITY CALIFORNIA, SAN DIEGO, La Jolla, CA
5Department of Cell and Developmental Biology, University of California at San Diego, School of Biological Sciences, La Jolla, CA
6Division of Bone and Marrow Transplantation, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA
7Division of Regenerative Medicine, UCSD, La Jolla, CA
8University of California San Diego, La Jolla, CA

Sandhya Dhiman1, Md. Hafiz Uddin2*, Vikram Dhillon, DO, MBA3,4,5*, Jeff Justin Aguilar, MD, MBA6, Amro Aboukameel2*, Husain Khan2*, Sahar Bannoura7*, Jay Yang, MD8, Gregory Dyson, PhD9*, Steven Buck10*, Asfar Azmi2*, Lisa Polin, PhD11,12*, Francis Burrows, PhD13*, Linda Kessler, BA13*, Jaroslaw Maciejewski14 and Suresh Kumar Balasubramanian, MD15

1Karmanos Cancer Institute/Wayne State University, Detroit, MI
2Karmanos Cancer Institute/ Department of Oncology, Wayne State University, Detroit, MI
3Department of Hematology/Oncology, Neal Cancer Center/Houston Methodist Hospital, Detroit, MI
4Department of Hematology/Oncology, Neal Cancer Center/Houston Methodist Hospital, Houston, TX
5Department of Oncology, Karmanos Cancer Center/Wayne State University, Detroit, MI
6Department of Internal Medicine, Detroit Medical Center, Detroit, MI
7Karmanos Cancer Institute/ Department of Oncology, Detroit, MI
8Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI
9Karmanos Cancer Institute/Department of Oncology, Wayne State University, Detroit, MI
10Wayne State University, Detroit, MI
11Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
12Department of Oncology, Wayne State University School of Medicine, Detroit, MI
13Kura Oncology, Carlsbad
14Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
15Department of Oncology, Karmanos Cancer Institute/ Wayne State University, Detroit, MI

Ton Falques, PhD*, Mattias Pilheden, PhD*, Larissa Helena Moura-Castro, PhD*, Qirui Zhang, PhD*, Louise Ahlgren, PhD*, Helena Sturesson, PhD*, Kajsa Paulsson, PhD, Axel Hyrenius Wittsten, PhD* and Anna K. Hagstroem-Andersson, PhD

Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden

Bogdan Popescu, MD1*, Madison Piao2*, Sydney Abelson3*, Carolina E. Morales, BS3*, Khadija Yousuf3*, Jose M. Rivera3*, Cheryl A C Peretz, MD3, Elliot Stieglitz, MD, PhD3 and Catherine C. Smith, MD2

1Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
2Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA
3Division of Hematology-Oncology, Dept. of Pediatrics, University of California San Francisco Benioff Children’s Hospital, San Francisco, CA

Brandon Turunen, PhD1*, Craig Leach, PhD1*, Matthew Smith2*, Terra L. Lasho, PhD2, Christy Finke, BS3*, Abhishek A. Mangaonkar, MBBS2, Aref Al-Kali, MD2, Yael Kusne, MD, PhD4, Talha Badar, MD5, James M. Foran, MD6, Aisha Margaert7*, Michelle Baptista1*, Stephanie Wiltzius1* and Mrinal M. Patnaik, MD, MBBS2

1Solu Therapeutics, Boston
2Mayo Clinic, Rochester, MN
3Division of Hematology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Phoenix, AZ
5Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
6Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
7Discovery Life Sciences, Seattle

John Pollard1*, Graham Craggs1*, Gillian Farnie2*, Matthew Fawkes1*, Fenella Gross1*, Joe Harman1*, Marta Llorca-Cardenosa1*, Sarah Major1*, Alison Maloney, PhD3*, Thomas A Milne4 and Iain Simpson1*

1Dark Blue Therapeutics, OXFORD, United Kingdom
2Cancer Research Horizons, The Francis Crick Institute, London, United Kingdom
3Dark Blue Therapeutics, OXFORD,, ENG, United Kingdom
4Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Mattia Vitale, PhD1*, Hollie B S Griffiths, PhD2*, Nyle Jones, PhD2*, Meera Mistry, MSc(Eng)2*, Jack Sangster, PhD2*, Chloe Patterson, PhD2*, Samuel E O'Halloran, PhD2*, Adrian Blanco-Gomez, PhD2*, Oliver Schon, PhD2* and Tiffany Thorn (nee Daniels), MSc2*

1Bivictrix Therapeutics Plc, Nether Alderley, United Kingdom
2BiVictriX Therapeutics plc, Nether Alderley, England, United Kingdom

Norman Fultang, PhD1*, Ashley M Schwab1*, Ian Johnson1*, Alexander Grego1*, Emma Filler1*, Carly Bachner1*, Jake Karwoski1*, Andrew Moore1*, Ashley Bartilomo1*, Anjana Agarwal1*, Olusola Peace Osinubi1*, Koichi Ito1*, Sarah Aminov, PhD2, Srabani Sahu, MS2*, Amit Verma, MD2, Peggy A Scherle, PhD1, Neha Bhagwat, PhD3 and Diane Heiser, PhD3*

1Prelude Therapeutics, Wilmington, DE
2Blood Cancer Institute, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY
3Prelude Therapeutics Incorporated, Wilmington, DE

Lucio Henrique Pinheiro, MSc1,2*, Isabel Weinhäuser, PhD3,4*, Diego A. Pereira-Martins, Ph.D.3,5*, Luise Araujo De Albuquerque Simoes, BS2,6*, Matthew Markham, PhD7*, Lynn Quek, MD, Ph.D.3*, Gerwin Huls4, Jan Jacob Schuringa, Prof. Dr.4, Stuart A Rushworth, PhD8 and Eduardo M. Rego, MD, PhD9

1Norwich Medical School, University of East Anglia, Norwich, ENG, United Kingdom
2Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, University of São Paulo Medical School, Sao Paulo, Brazil
3Myeloid Leukaemia Genomics and Biology Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
4Department of Experimental Hematology, University Medical Center Groningen, Groningen, Netherlands
5Department of Experimental Hematology, University Medical Centre Groningen, Groningen, Netherlands
6Department of Experimental Hematology, University Medical Center Groningen, São Paulo, SP, Brazil
7Norwich Medical School, University of East Anglia, Norwich, United Kingdom
8University of East Anglia, Norwich, United Kingdom
9Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, University of São Paulo Medical School, São Paulo, São Paulo, Brazil

Heather Betz1,2* and Xiaoyan Jiang, MD, PhD1,2

1Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC, Canada
2Department of Medicine, The University of British Columbia, Vancouver, BC, Canada

Dhabya Majid, BS1*, Zhe WANG, MD1*, Bin Yuan, PhD2*, Mhd Yousuf Yassouf, PhD3*, Amanda Schalk, PhD4*, Basant T. Gamal, MS5*, Qi Zhang Tatarata, MD, PhD1*, Jessica Lynn Root, MS6*, Araceli Isabella Garza1*, Annie Hoai Nguyen7*, Sammy Ferri-Borgogno, PhD5*, Patrick K. Reville, MD, MPH1, Arnon Lavie, PhD4* and Hussein A. Abbas, MD, PhD1,8

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2The University of Texas at MD Anderson Cancer center, Houston, TX
3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
4University of Illinois, Chicago, IL
5University of Texas MD Anderson Cancer Center, Houston
6Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX
7Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston
8Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Matthew Tcheng, BSc1,2*, Veronique Voisin, PhD2*, Marcela Gronda2*, Rose Hurren3*, Dakai Ling2*, Yongran Yan2*, Lan Xin Zhang4*, Yue Feng2*, Zaynab Mamai5*, Yulia Jitkova2*, Chaitra Sarathy, PhD2*, Andrea Arruda6*, Steven M. Kornblau, MD7, Mark D. Minden, MD, PhD6,8,9* and Aaron D Schimmer, MD10

1University Health Network, Princess Margaret Cancer Research Tower, Richmond Hill, ON, Canada
2University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
3UHN, Princess Margaret Cancer Centre, Toronto, ON, Canada
4University Health Network, Princess Margaret Cancer Center, Toronto, ON, Canada
5University of Toronto, Toronto, ON, Canada
6Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
10Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

*signifies non-member of ASH